Progestin stimulation of thymidine kinase in the human breast cancer cell line T47D.
Our laboratory has previously reported that progestins stimulate growth of the human breast cancer cell line T47D. In an attempt to probe further into this stimulation, we are investigating progestin effects on thymidine kinase (EC 2.7.1.21), an enzyme known to be involved in growth regulation. This report relates our finding that progestins stimulate thymidine kinase activity, at physiological progestin concentrations, in a dose-responsive manner. Estradiol-17 beta also stimulates, but testosterone, hydrocortisone and aldosterone do not. The antiprogestin RU486 inhibits progestin stimulation, but also stimulates on its own. Maximal by 24 h, the progestin stimulation then falls off with time. Experiments with actinomycin D and cycloheximide suggest that the thymidine kinase stimulation depends on new RNA and protein synthesis. These data shed further light on progestin stimulation of the growth of human breast cancer. To our knowledge, this is the first report of progestin stimulation of thymidine kinase in human breast cancer cells.
Moore
M R
MR
Department of Biochemistry, Marshall University School of Medicine, Huntington, WV 25704.
Hathaway
L D
LD
Bircher
J A
JA
D001943:Breast Neoplasms / Q000201:enzymology* / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D003609:Dactinomycin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D066298:In Vitro Techniques; D015735:Mifepristone / Q000494:pharmacology; D011372:Progestins / Q000494:pharmacology*; D011397:Promegestone / Q000494:pharmacology; D013937:Thymidine Kinase / Q000378:metabolism*; D013997:Time Factors; D014407:Tumor Cells, Cultured
D011372:Progestins; D003609:Dactinomycin; D015735:Mifepristone; D011397:Promegestone; D013937:Thymidine Kinase